Business Description
Inogen Inc
NAICS : 325412
SIC : 3842
ISIN : US45780L1044
Share Class Description:
STU:6IO: Ordinary SharesTotal Employee Number:
753Description
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.51 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -1.47 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.63 | |||||
Beneish M-Score | -2.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -7.4 | |||||
3-Year EBITDA Growth Rate | 5 | |||||
3-Year EPS without NRI Growth Rate | 36.1 | |||||
3-Year FCF Growth Rate | 31.9 | |||||
3-Year Book Growth Rate | -18.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 28.71 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.24 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.57 | |||||
9-Day RSI | 49.52 | |||||
14-Day RSI | 49.87 | |||||
3-1 Month Momentum % | -4.2 | |||||
6-1 Month Momentum % | 19.75 | |||||
12-1 Month Momentum % | 5.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.1 | |||||
Quick Ratio | 2.7 | |||||
Cash Ratio | 1.79 | |||||
Days Inventory | 47.22 | |||||
Days Sales Outstanding | 40.77 | |||||
Days Payable | 41.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.9 | |||||
Shareholder Yield % | 2.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 44.31 | |||||
Operating Margin % | -9.07 | |||||
Net Margin % | -7.08 | |||||
EBITDA Margin % | -3.28 | |||||
FCF Margin % | -2.92 | |||||
OCF Margin % | -0.32 | |||||
ROE % | -12.84 | |||||
ROA % | -8.23 | |||||
ROIC % | -21.89 | |||||
3-Year ROIIC % | -9.57 | |||||
ROC (Joel Greenblatt) % | -43.12 | |||||
ROCE % | -13.4 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.52 | |||||
PB Ratio | 1 | |||||
Price-to-Tangible-Book | 1.25 | |||||
EV-to-EBIT | -2.63 | |||||
EV-to-EBITDA | -7.3 | |||||
EV-to-Revenue | 0.24 | |||||
EV-to-FCF | -8.64 | |||||
Price-to-GF-Value | 0.94 | |||||
Price-to-Median-PS-Value | 0.22 | |||||
| Price-to-Net-Current-Asset-Value | 2.04 | |||||
| Price-to-Net-Cash | 25.68 | |||||
Earnings Yield (Greenblatt) % | -37.98 | |||||
FCF Yield % | -5.77 | |||||
Forward Rate of Return (Yacktman) % | -12.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inogen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 302.129 | ||
| EPS (TTM) (€) | -0.781 | ||
| Beta | 0.6798 | ||
| 3-Year Sharpe Ratio | 0.06 | ||
| 3-Year Sortino Ratio | 0.1 | ||
| Volatility % | 33.96 | ||
| 14-Day RSI | 49.87 | ||
| 14-Day ATR (€) | 0.207626 | ||
| 20-Day SMA (€) | 5.64 | ||
| 12-1 Month Momentum % | 5.56 | ||
| 52-Week Range (€) | 4.46 - 7.65 | ||
| Shares Outstanding (Mil) | 27.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inogen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inogen Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 08:30 | In 92 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 91 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 17:00 | In 1 day | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 5.95 (+3.48%) | ||
| General meeting for 2026 | 2026-06-05 13:00 | 5.40 (+5.88%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 17:00 | 6.00 (+0.84%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 6.00 (+0.84%) | ||
| the 25th Annual Needham Virtual Healthcare Conference | 2026-04-14 10:15 | 5.50 (+3.77%) | ||
| e KeyBanc Virtual Life Sciences & MedTech Investor | 2026-03-17 15:00 | 5.25 (+0.00%) | ||
| Annual report for 2025 | 2026-02-27 | 5.45 (+7.92%) |
Show
Entries
Inogen Inc Frequently Asked Questions
What is Inogen Inc(STU:6IO)'s stock price today?
The current price of STU:6IO is €5.65. The 52 week high of STU:6IO is €7.65 and 52 week low is €4.46.
When is next earnings date of Inogen Inc(STU:6IO)?
The next earnings date of Inogen Inc(STU:6IO) is 2026-08-06.
Does Inogen Inc(STU:6IO) pay dividends? If so, how much?
Inogen Inc(STU:6IO) does not pay dividend.
Press Release
Articles on Inogen Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers